
Sign up to save your podcasts
Or
Special guest Steven E. Nissen, MD, MACC, the Chief Academic Officer at the Heart and Vascular Institute, Lewis and Patricia Dickey Chair in Cardiovascular Medicine, and Professor of Medicine at the Cleveland Clinic Lerner School of Medicine at Case Western Reserve University joins us to talk about non-statins for LDL lowering.
Listen in as they debate which non-statin to use for LDL lowering...due to recent headlines about bempedoic acid.
You’ll also hear practical advice from panelists on TRC’s Editorial Advisory Board:
For the purposes of disclosure, Dr. Steven Nissen reports relevant financial relationships [cardiology] with AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Esperion, Medtronic, MyoKardia, New Amsterdam Pharma, Novartis, Pfizer, Silence Therapeutics (grants/research support). The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.
Pharmacist’s Letter offers CE credit for this podcast. Log in to your Pharmacist’s Letter account and look for the title of this podcast in the list of available CE courses.
If you’re not yet a Pharmacist’s Letter subscriber, find out more about our product offerings at trchealthcare.com.
Follow or subscribe, rate, and review this show in your favorite podcast app. You can also reach out to provide feedback or make suggestions by emailing us at [email protected].
4.3
4646 ratings
Special guest Steven E. Nissen, MD, MACC, the Chief Academic Officer at the Heart and Vascular Institute, Lewis and Patricia Dickey Chair in Cardiovascular Medicine, and Professor of Medicine at the Cleveland Clinic Lerner School of Medicine at Case Western Reserve University joins us to talk about non-statins for LDL lowering.
Listen in as they debate which non-statin to use for LDL lowering...due to recent headlines about bempedoic acid.
You’ll also hear practical advice from panelists on TRC’s Editorial Advisory Board:
For the purposes of disclosure, Dr. Steven Nissen reports relevant financial relationships [cardiology] with AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Esperion, Medtronic, MyoKardia, New Amsterdam Pharma, Novartis, Pfizer, Silence Therapeutics (grants/research support). The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.
Pharmacist’s Letter offers CE credit for this podcast. Log in to your Pharmacist’s Letter account and look for the title of this podcast in the list of available CE courses.
If you’re not yet a Pharmacist’s Letter subscriber, find out more about our product offerings at trchealthcare.com.
Follow or subscribe, rate, and review this show in your favorite podcast app. You can also reach out to provide feedback or make suggestions by emailing us at [email protected].
534 Listeners
98 Listeners
481 Listeners
687 Listeners
254 Listeners
3,330 Listeners
21 Listeners
1,365 Listeners
1,095 Listeners
693 Listeners
151 Listeners
362 Listeners
36 Listeners
5 Listeners
4 Listeners